Illumina

Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan | CNBCCarl Icahn on Thursday expressed his support for Illumina's new CEO Jacob Thaysen – a relief for the company as it tries to rebound from a bitter…

A building on the campus at the world headquarters of Illumina is shown in San Diego, California, Sept. 1, 2021.Mike Blake | ReutersThe U.S. Securities and Exchange Commission is investigating Illumina over its controversial $7.1 billion…

Illumina, the US genetic testing company has been fined by the European Union for a record 432 million euros (USD 476 million) on Wednesday (July 12). The fine has been imposed for closing its takeover of cancer test maker Grail without…

Rafael Henrique | Lightrocket | Getty ImagesEuropean Union regulators on Wednesday fined Illumina a record 432 million euros ($476 million) for closing its acquisition of cancer test developer Grail without first securing regulatory…

Rafael Henrique | Lightrocket | Getty ImagesRepublican lawmakers, state attorneys general and several advocacy groups have voiced their support for Illumina's acquisition of cancer test developer Grail while the Federal Trade Commission…

Francis deSouza, chief executive officer of Illumina Inc., during a panel session on day three of the World Economic Forum (WEF) in Davos, Switzerland, on Thursday, Jan. 19, 2023.Stefan Wermuth | Bloomberg | Getty ImagesIllumina on Sunday…

Rafael Henrique | Lightrocket | Getty ImagesActivist investor Carl Icahn on Thursday won enough support from Illumina shareholders to install one of his three nominees to the biotech company's board of directors. Shareholders also ousted…

Is Icahn on the cusp of a big win? One of the biggest fights in corporate America is coming to a head on Thursday: Shareholders in Illumina, the gene-sequencing giant, are set to vote on whether to back the company’s incumbent directors or…

Carl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan | CNBCCarl Icahn on Friday called Illumina's first-quarter results "very disappointing" and slammed the DNA sequencing company's new plans to cut costs. …

Illumina CEO Francis deSouza on Wednesday touted the company's controversial acquisition of Grail after revenue from the cancer test developer doubled in the last year. The Grail deal is the focus of a heated proxy fight between Illumina…